Kerisha Naidoo

Kerisha Naidoo is an accomplished healthcare executive currently serving as the Global Immunology Lead for Growth & Emerging Markets at Takeda since March 2025. Naidoo holds multiple advisory roles, including membership on the Advisory Council for Harvard Business Review and serving as an Angel Investor at she1K. Previously, Naidoo led Strategy & Innovation and oversaw the Global Inflammation & Rare Disease Pipeline at Amgen, where responsibilities included medical affairs and strategic launch planning across various therapeutic areas in JAPAC. Naidoo's extensive experience also includes leadership positions at Biogen, AbbVie, Abbott, Solvay Pharmaceuticals, NHS, and MD Anderson Cancer Center. Education credentials comprise an Executive MBA from Harvard Business School, PharmD and Masters of Pharmacy from the University of Sydney, and an MBA from Macquarie Business School.